Merge Technologies makes management moveConnectivity and PACS firm Merge Technologies has named Joseph Gentile director of worldwide system sales. Gentile will manage the Milwaukee, WI, firm’s systems solution group, which provides medical
Connectivity and PACS firm Merge Technologies has named Joseph Gentile director of worldwide system sales. Gentile will manage the Milwaukee, WI, firms systems solution group, which provides medical connectivity products and medical information appliances and servers. The company expects Gentiles experience as vice president of sales of IMACS Medical, which created a networked data and information management system for cardiology, to help it boost its business.
In other Merge news, the company last month began shipping its second-generation medical image information server MergeARK to facilities in Europe. MergeARK is part of the firms MergeWorks suite of products, and has been upgraded to improve its storage, retrieval, and reprint capacities. MergeARKs hardware and operating system software are now based on Dell servers and Red Hat Linux version 6.0, respectively. Some of Merges European installations of MergeARK will include DRM-7000, a CD-R library from Pioneer that can store 670 CDs to provide data storage of more than 400 gigabytes.
© 2000 Miller Freeman, Inc., a United News & Media company
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.